Genflow Bioscience

The potential to extend healthy lifespan with groundbreaking science

The SIRT6 gene is recognized as a master regulator of healthy aging.  SIRT6 overexpression has been shown to lead to a healthy lifespan extension in both male and female mice.  Genflow Biosciences intends to promote healthy aging by providing extra copies of a variant of the Human SIRT6 gene found in centenarians. Genflow Biosciences is developing an ethical, safe and efficient gene delivery system to deliver this centenarian variant of SIRT6. gene.

The Products Pipeline

Our Lead Compound GF-1002

A 120-minute infusion of AAV vectors allows a safe transient episomal expression of extra copies of a centenarian variant of the SIRT6 gene without integration into the DNA, without risk of self-replication, without transfer of bacterial genetic material, without immunogenic or mutagenesis concerns. 

GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. It is a recombinant self-complementary AAV containing a transgene encoding the cDNA portion of a variant of the human SIRT6 gene found in centenarians developed as a treatment of Werner Syndrome.

GF-4001 is a non-Human version of GF-1002 anti-aging gene therapy developed for veterinary use (dogs).

GF-2001  is an inhaled formulation for idiopathic Pulmonary Fibrosis of an adeno-associated viral vector-based gene therapy. It is a recombinant AAV with lung tropism containing a transgene encoding the cDNA portion of a variant of the human SIRT6 gene found in centenarians.

Clinical Programs

First-in-man proof-of-concept phase I/II trial in werner syndrome

Genflow Biosciences is on the fast track to become a top performing biotechnological powerhouse. An aggressive clinical development plan is underway. A team of seasoned industry leaders leads with confidence knowing there is short-term milestone potential.

Stay up to date with our progress, news and more